Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: arnie h who wrote (831)	6/18/1999 3:25:00 PM
From: yosi s	Read Replies (1) \| Respond to of 1386

..." And the company is popping 7M more shares into the hopper diluting us even more. "... "The fact that the price didn't head further south on the recent S3 filing seems to add comfort." Please note the recent filing is for point of information and regulatory purposes. We know about it when they got the line of credit. It just give Pharmos the leverage to put the shares on the market at the best price in the future without moving the market. That is why it caused little effect. As far as sales of Lotemax and Alrex, I would not be surprised if sales double from last Q. (that is with current marketing effort.) I agree that Pharmos can do better. Once Letobra is out as well as EC market is reached. As for Cohort 3 it is on. just about done enrolling, I would suspect. Also clinical information should continue to do well. Same goes for mortality.....So phase 2 results are expected to be repeated. I do not understand why it takes so long to come with a partnering agreement. Short of that how it takes to negotiate a deal... Things do seem to take forever, once waiting for a deal. And no times at all once a deal was made...